Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Employee Benefits topic
No spam. Unsubscribe anytime.
Board asks insurance committee to study GLP-1 drug costs after spike in cash prices
Summary
Board members flagged recent retail prices for GLP-1 drugs (Wegovy/Ozempic) and asked the district insurance committee and Brown & Brown to evaluate coverage options to reduce employee and district pharmacy spend; staff said options will be proposed to the insurance committee and returned to the board.
At the workshop, board members raised concern about sharply lower cash retail prices for GLP-1 drugs and potential impacts on the district's health-care spend. One board member noted new cash prices of about $200 for initial months and $350 thereafter and asked whether the district could lower its costs by adjusting insurance or using an outside vendor arrangement similar to discount platforms. “Are they gonna lower the prices for the insurance companies as well, or how will that change?” a board member asked.
Staff and a Brown & Brown representative said they are evaluating options and will present proposals to the insurance committee, stressing that any changes should preserve coverage for employees with diabetes and other qualifying conditions while reducing overall spend. “Brown and Brown has been providing those updates to us, and they are going to draft some options to the insurance committee,” a district staff member said.
Board members asked for comparisons between cash-pricing alternatives (GoodRx-style vendor) and current in-insurance costs, and requested an analysis of trigger criteria the district uses to authorize coverage. Staff said the district's PBM and pharmaceutical spend are major cost drivers and that cost reductions could be substantial; they committed to bring specific options and cost estimates back to the insurance committee and then to the board.
